United Therapeutics
UTHR
394 hedge funds and large institutions have $5.72B invested in United Therapeutics in 2016 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 133 increasing their positions, 161 reducing their positions, and 34 closing their positions.
35% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 34
9% more capital invested
Capital invested by funds: $5.24B → $5.72B (+$475M)
3% more funds holding
Funds holding: 384 → 394 (+10)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
17% less repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 161
39% less call options, than puts
Call options by funds: $23.6M | Put options by funds: $38.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$48.1M |
| 2 |
Citigroup
New York
|
+$31.2M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$27.8M |
| 4 |
APG Asset Management
Amsterdam,
Netherlands
|
+$21.3M |
| 5 |
FQ
First Quadrant
Glendale,
California
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$102M |
| 2 |
Goldman Sachs
New York
|
-$31M |
| 3 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
-$29.6M |
| 4 |
SCM
Scopia Capital Management
New York
|
-$25.1M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$19.6M |
UTHR Hedge Fund Activity: Q3 2016 in Review
394 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2016, worth a combined $5.72B — up 9.1% from $5.24B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new UTHR positions and 34 closed out — a net gain of 12 holders — while 133 added to existing stakes and 161 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $48.1M. The largest seller was Deutsche Bank, cutting an estimated $102M.
- 394 institutional investors held United Therapeutics (UTHR) as of Q3 2016, up from 384 in Q2 2016.
- Funds reported $5.72B of United Therapeutics stock for Q3 2016, up 9.1% quarter-over-quarter.
- 46 funds opened new United Therapeutics positions in Q3 2016 and 34 closed out, a net change of +12 holders.
- The largest United Therapeutics buyer in Q3 2016 was Consonance Capital Management, an estimated $48.1M added.
- The largest United Therapeutics seller in Q3 2016 was Deutsche Bank, an estimated $102M sold.
Based on aggregated 13F filings for Q3 2016.